Bolt Biotherapeutics, Inc.
BOLTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M | $231,000 |
| Operating income | −$36.1M | −$73.0M | −$76.2M | −$90.3M | −$92.8M | −$49.2M |
| Net income | −$33.4M | −$63.1M | −$69.2M | −$88.1M | −$98.6M | −$60.7M |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M | $46.5M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M | $46.2M |
| Equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M | −$104.9M |
| EPS (diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | — |
| Shares out. | 38.3M | 38.1M | 37.8M | 37.5M | 37.4M | 2.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −469.3%
- Net margin
- −433.7%
- Return on equity
- −125.9%
- Return on assets
- −58.8%
- Return on capital (ROCE)
- −74.7%
- Liabilities / assets
- 53.3%
- Debt / equity
- 1.14×
- Book value / share
- $0.69
- Revenue growth (YoY)
- 0.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -27.30distress
- Accruals / assets
- 11.4%high accruals
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pivotal Bioventure Partners Fund I, L.P.Activist (13D)Feb 26, 2026
- Vivo Panda Fund, L.P.Passive (13G)Feb 13, 2026
- Tang Capital Management LlcPassive (13G)Nov 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Quinn William P.Officer — President, CEO and CFO | Dec 5, 2025 | Buy | 125 | $4.61 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 12,126 | 1.0 | +73.3% |
| Apr 30, 2026 | 6,999 | 1.0 | -69.2% |
| Apr 15, 2026 | 22,704 | 1.0 | +355.3% |
| Mar 31, 2026 | 4,987 | 1.0 | +449.2% |
| Mar 13, 2026 | 908 | 1.0 | -51.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Results of operationsMar 12, 2026
- Results of operationsNov 12, 2025
- Costs from exit or disposal · Other material eventOct 2, 2025
- Results of operationsAug 14, 2025
- Delisting / listing-standard notice · Amended charter or bylawsJun 6, 2025
- Other material eventJun 4, 2025
- Shareholder voteMay 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 12, 2026
- 8-KMay 12, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- S-8Mar 12, 2026
- 10-KMar 12, 2026
- 8-KMar 12, 2026
- SCHEDULE 13D/AFeb 26, 2026
- SCHEDULE 13D/AFeb 17, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 4Feb 4, 2026
- 4Feb 4, 2026
- 4Feb 4, 2026
- 4Dec 16, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.